Company profile: NuSirt
1.1 - Company Overview
Company description
- Provider of biotechnology solutions developing a patented leucine-metformin combination designed to reduce the side effects of metformin while maintaining its effectiveness in controlling blood sugar levels in Type 2 diabetes patients.
Products and services
- Leucine-Metformin Combination: A patented blend of leucine and metformin that reduces metformin side effects while preserving glycemic control effectiveness in Type 2 diabetes patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NuSirt
Satiogen
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies targeting type 2 diabetes, offering metabolic mechanism therapy designed to regulate nutrient intake and postprandial glucose. Products include a substitute for metformin in gliptin formulations and an OTC nutraceutical.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satiogen company profile →
Diabetomics
HQ: United States
Website
- Description: Provider of non-invasive medical diagnostics for personalized health and diabetes risk, offering point-of-care tests: Glucema saliva test for diabetes monitoring via glycosylated proteins; Lumella blood test for early preeclampsia via glycosylated fibronectin; Insudex for early type-1 diabetes and LADA via autoantibody titers; RAprime for rheumatoid arthritis from oral fluid or finger stick; CovAb oral-swab COVID-19 antibody test detecting IgA/IgM/IgG.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diabetomics company profile →
JanOne
HQ: United States
Website
- Description: Provider of pharmaceutical drug candidates targeting severe pain conditions, including JAN101, a twice-daily slow-release oral sodium nitrite formulation for treatment and prevention of peripheral artery disease (PAD) and associated pain, and Jan123, a low-dose naltrexone candidate for complex regional pain syndrome delivered via a unique oral biphasic release tablet.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JanOne company profile →
Osler Diagnostics
HQ: United Kingdom
Website
- Description: Provider of portable, low-cost, quick, and easy-to-use lab-quality diagnostics, featuring the Osler Origin 'portable lab' for a wide range of tests across healthcare settings. Offers lab-in-your-hand technology with microfluidic sample preparation and electrochemical biosensing, HemaTap sample addition for simplified cartridges, and a comprehensive test menu.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Osler Diagnostics company profile →
SmartCells
HQ: United States
Website
- Description: Provider of insulin and polymer-based products for diabetes, including SmartInsulin, a self-regulating injectable formulation, and polymer-based dosing technology for applications in fertility, thyroid, and growth hormone deficiencies, and treatments with poor compliance or therapeutic window.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartCells company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NuSirt
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NuSirt
2.2 - Growth funds investing in similar companies to NuSirt
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NuSirt
4.2 - Public trading comparable groups for NuSirt
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →